

Company Overview

Molecular Templates is focused on the discovery, development, and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases.

Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

Dec 19 2024, 4:10 PM EST

Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements

Dec 2 2024, 5:06 PM EST

Molecular Templates, Inc. Reports Second Quarter 2024 Financial Results and Corporate Update

Aug 14 2024, 4:21 PM EDT

Stock Overview

Symbol	MTEM
Exchange	Nasdaq
Market Cap	243.6k
Last Price	\$0.03
52-Week Range	\$0.01 - \$4.12

01/06/2025 08:50 PM EST

Investor Relations

Dr. Grace Kim
grace.kim@mtem.com

Management Team

Kristen Quigley

Chief Operating Officer

Grace Kim

Chief Strategy Officer & Head of Investor Relations

Michelle Iwamoto-Fan, Ph.D., J.D.

Senior Vice President and General Counsel

Chris Moore, Ph.D.

Senior Vice President and Head of Preclinical Development and Translational Medicine

Joseph Phillips, Ph.D.

Senior Vice President and Head of CMC Development

Molecular Templates, Inc.

9301 Amberglen Blvd
Suite 100
Austin, TX 78729

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.